Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background Episodes of depression are the most frequent cause of disability among patients with bipolar disorder. The effectiveness and safety of standard antidepressant agents for depressive episodes associated with bipolar disorder (bipolar depression) have not been well studied. Our study was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania. Methods In this double-blind, placebo-controlled study, we randomly assigned subjects with bipolar depression to receive up to 26 weeks of treatment with a mood stabilizer plus adjunctive antidepressant therapy or a mood stabilizer plus a matching placebo, under conditions generalizable to routine clinical care. A standardized clinical monitoring form adapted from the mood-disorder modules of the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, was used at all follow-up visits. The primary outcome was the percentage of subjects in each treatment group meeting the criterion for a durable recovery (8 consecutive weeks of euthymia). Secondary effectiveness outcomes and rates of treatment-emergent affective switch (a switch to mania or hypomania early in the course of treatment) were also examined. Results Forty-two of the 179 subjects (23.5%) receiving a mood stabilizer plus adjunctive antidepressant therapy had a durable recovery, as did 51 of the 187 subjects (27.3%) receiving a mood stab…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on negative placebo‐controlled data, we do not recommend paroxetine (level 2 negative).245”
In the citing paper
“Antimanic medications reduce depressive symptoms in only one-third of patients (2).”
From Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial (2018) · cites this paper as [2]
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Prevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
Extending Indications for Long-Term Pharmacotherapy: Opportunities and Challenges
Kane, J. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.1 · Cited by 987
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationPerlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689
Self-citationPrevalence and Treatment of Mental Disorders
(2005) · New England Journal of Medicine · doi:10.1056/nejmc051936 · Cited by 650
Research works printed but not linked: 4
- Murray CJ, 1994, Bull World Health Organ, 72, 495
- Sheehan DV, 1998, J Clin Psychiatry, 59, 22
- Sachs GS, 1994, J Clin Psychiatry, 55, 391
- 10.1037/0021-843X.108.4.579 · doi:10.1037/0021-843x.108.4.579 · Paper page
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
“Further, several small crossover trials demonstrated significantly higher response rates to lithium than placebo in patients with acute bipolar depression (245).”
BackgroundSelf-citationGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
“compared paroxetine and bupropion with placebo and the results were certainly negative (Sachs et al., 2007).”
Self-citationYatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
“For instance, OFC was shown to be more effective than placebo or olanzapine monotherapy (93, 95), but the combination of paroxetine or bupropion with a mood stabilizer was not more effective than a mood stabilizer plus placebo (124).”
BackgroundWisner, K. L., Sit, D. K. Y., McShea, M. C., Rizzo, D. M., Zoretich, R. A., Hughes, C. L., Eng, H. F., Luther, J. F., Wisniewski, S. R., Costantino, M. L., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.87 · Cited by 1,091
“Treatment of the depressed phase of bipolar disorder with a mood stabilizer and an antidepressant does not confer benefit beyond treatment with a mood stabilizer alone.(60) Given the critical importance of birth as a life event for families, detection and treatment of bipolar disorder among childbearing women has majo…”
BackgroundSelf-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
“Compared with our previous study with ketamine in patients with treatment-resistant major depressive disorder,(34) we found (1) more rapid onset of antidepressant effects (40 vs 110 minutes), (2) a higher response rate at 40 minutes (56% vs 11%) but lower at day 1 (42% vs 71%), (3) similar remission rates at day 1 (31…”
ResultGeddes, J. R., & Miklowitz, D. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60857-0 · Cited by 848
Self-citationPacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020185 · Cited by 770
“In a previously described 6-month double-blind placebo-controlled trial (25), rates of mood elevations were indistinguishable (10.”
BackgroundSelf-citationNational Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730
Yatham, L. N., Kennedy, S. H., Schaffer, A., Parikh, S. V., Beaulieu, S., O'Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., Ravindran, A., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00672.x · Cited by 570
“The STEP-BD study, comparing adjunctive antidepressants (bupropion or paroxetine) plus lithium or divalproex and lithium or divalproex alone, for up to 26 weeks, included 114 patients with BD II (67).”
BackgroundMethodSelf-citationBerk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Bolton, J. M., Robinson, J., & Sareen, J. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.003 · Cited by 448
Neurocognitive Mechanisms in Depression: Implications for Treatment
Clark, L., Chamberlain, S. R., & Sahakian, B. J. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125618 · Cited by 446
Goodwin, G., & Consensus Group of the British Association for Psychopharmacology (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102919 · Cited by 444
Geddes, J. R., Calabrese, J. R., & Goodwin, G. M. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048504 · Cited by 434
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
“World Journal of Biological Psychiatry 2013, 14(3), 154-219.”
BackgroundSelf-citationAngst, J. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.87 · Cited by 417
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
“Paroxetine lithium or valproate D 5 (Nemeroff et al. 2001; Sachs et al. 2007; Vieta et al. 2002; Young et al. 2000) Paroxetine: 20–50 mg (Nemeroff et al.”
BackgroundResultInfluentialSelf-citationKosorok, M. R., & Laber, E. B. (2019) · Annual Review of Statistics and Its Application · doi:10.1146/annurev-statistics-030718-105251 · Cited by 370
“They demonstrate the validity of the inference through simulation studies and apply the method to the STEP-BD study data on bipolar disorder (Sachs et al 2007).”
MethodBaldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359
“Further, the efficacy of antidepressants in bipolar depression (BD) has been challenged (Sachs et al. 2007; Pacchiarotti et al. 2013) and fewer treatment options are available than for MDD (Vieta et al. 2010).”
BackgroundMcElroy, S. L., Weisler, R. H., Chang, W., Olausson, B., Paulsson, B., Brecher, M., Agambaram, V., Merideth, C., Nordenhem, A., Young, A. H., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04942gre · Cited by 328
“The common practice of employing antidepressants (often as monotherapy) to treat bipolar I and in particular bipolar II depressed patients appears to need reexamination by clinicians in light of this study and the STEP-BD results.(16)”
BackgroundGoldberg, J. F., Perlis, R. H., Bowden, C. L., Thase, M. E., Miklowitz, D. J., Marangell, L. B., Calabrese, J. R., Nierenberg, A. A., & Sachs, G. S. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050746 · Cited by 322
“The study participants were 1,380 individuals with bipolar I (N=401) or II (N=979) disorder who met the DSM-IV criteria for a major depressive episode at the time of entry into the Systematic Treatment Enhancement Program for Bipolar Disorder (STEPBD), a 22-site study sponsored by the National Institute of Mental Heal…”
Self-citationJensen, N. H., Rodriguiz, R. M., Caron, M. G., Wetsel, W. C., Rothman, R. B., & Roth, B. L. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301646 · Cited by 316
“Recent observations indicate that the Neuropsychopharmacology use of adjunctive, standard antidepressant medication in the treatment of bipolar depression, as compared with the use of mood stabilizers, such as lithium or valproate alone, does not increase antidepressant efficacy (Sachs et al, 2007).”
BackgroundNery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298
“The findings are consistent with evidence for the involvement of inflammatory abnormalities in the pathophysiology of mood disorders, and they add evidence to the literature about the potential role of cox-2 inhibitors in the treatment of bipolar depression, a condition for which available treatment are limited (Sachs…”
BackgroundResultSelf-citationPharmacological treatment of adult bipolar disorder
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0044-2 · Cited by 272
Miklowitz, D. J., Otto, M. W., Frank, E., Reilly-Harrington, N. A., Kogan, J. N., Sachs, G. S., Thase, M. E., Calabrese, J. R., Marangell, L. B., Ostacher, M. J., et al. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07020311 · Cited by 274
“Details of the sampling procedures are given elsewhere (11, 12).”
Self-citationde Almeida, J. R. C., & Phillips, M. L. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.010 · Cited by 277
Wu, J. C., Kelsoe, J. R., Schachat, C., Bunney, B. G., DeModena, A., Golshan, S., Gillin, J. C., Potkin, S. G., & Bunney, W. E. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.02.018 · Cited by 263
“he relatively low response rate in the MED group (22%) is onsistent with results from the Systematic Treatment Enhanceent Program for BPD (STEP-BD) study (23%) (16).”
ResultHyman, S. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003142 · Cited by 260
Mania associated with antidepressant treatment: comprehensive meta‐analytic review
Tondo, L., Vázquez, G., & Baldessarini, R. J. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01514.x · Cited by 256
“However, TCAs did not differ from modern ADs [SRIs + SNRIs + bupropion; (df = 71), F = 2.43; P = 0.123], nor did MAOIs differ significantly from modern ADs: [(df = 39) F = 1.57; P = BPD, bipolar disorder; MDD, major depressive disorder; RCT, randomized controlled trial.”
BackgroundInfluentialA Placebo-Controlled Evaluation of Adjunctive Modafinil in the Treatment of Bipolar Depression
Frye, M. A., Grunze, H., Suppes, T., McElroy, S. L., Keck, P. E., Walden, J., Leverich, G. S., Altshuler, L. L., Nakelsky, S., Hwang, S., et al. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06060981 · Cited by 249
Family‐Focused Therapy for Bipolar Disorder: Reflections on 30 Years of Research
Miklowitz, D. J., & Chung, B. (2016) · Family Process · doi:10.1111/famp.12237 · Cited by 243
“Interestingly, in an overlapping randomized trial, STEP-BD investigators found no benefit of adding antidepressants to mood stabilizers in stabilizing patients with bipolar depression (Sachs et al., 2007).”
BackgroundSelf-citationBipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Differential diagnosis of bipolar disorder and major depressive disorder
Hirschfeld, R. M. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70004-7 · Cited by 234
“, 2003), adjunctive use of these antidepressants has shown modest efficacy at best (Nemeroff et al., 2001; Post et al., 2001; Sachs et al., 2007).”
BackgroundSubthreshold Hypomanic Symptoms in Progression From Unipolar Major Depression to Bipolar Disorder
Fiedorowicz, J. G., Endicott, J., Leon, A. C., Solomon, D. A., Keller, M. B., & Coryell, W. H. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10030328 · Cited by 228
Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a meta‐analysis
Dierckx, B., Heijnen, W. T., van den Broek, W. W., & Birkenhäger, T. K. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.00997.x · Cited by 224
Kapczinski, F., Magalhães, P. V. S., Balanzá‐Martinez, V., Dias, V. V., Frangou, S., Gama, C. S., Gonzalez‐Pinto, A., Grande, I., Ha, K., Kauer‐Sant'Anna, M., et al. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12305 · Cited by 217
“(24) also examined whether there were any differential responses to adjunctive antidepressants within the STEP-BD study (35).”
BackgroundGoldberg, J. F., Perlis, R. H., Ghaemi, S. N., Calabrese, J. R., Bowden, C. L., Wisniewski, S., Miklowitz, D. J., Sachs, G. S., & Thase, M. E. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05122032 · Cited by 217
Self-citationThe vigilance regulation model of affective disorders and ADHD
Hegerl, U., & Hensch, T. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.10.008 · Cited by 212
“LIFE is funded by eans of the European Union, by the European Regional Develpment Fund (ERDF) and by means of the Free State of Saxony owski (2012), Sachs et al. (2007).”
The Neurobiology of the Switch Process in Bipolar Disorder: A Review
Salvadore, G., Quiroz, J. A., Machado-Vieira, R., Henter, I. D., Manji, H. K., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05259gre · Cited by 209
“Lewis & Winokur, 1982 38 None required Retrospective DSM-III mania while hospitalized or within 6 months of discharge Cohn et al., 1989 42 6 weeks RCT Not specified Himmelhoch et al, 1991 40 8 weeks RCT DSM-IIIR mania or hypomania Altshuler et al., 1995 8 weeks Retrospective Mania within 8 weeks of the initiation of A…”
InfluentialRamasubbu, R., Taylor, V. H., Samaan, Z., Sockalingham, S., Li, M., Patten, S., Rodin, G., Schaffer, A., Beaulieu, S., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400110 · Cited by 206
Bipolar II disorder: arguments for and against a distinct diagnostic entity
Vieta, E., & Suppes, T. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00561.x · Cited by 200
Frye, M. A., Helleman, G., McElroy, S. L., Altshuler, L. L., Black, D. O., Keck, P. E., Nolen, W. A., Kupka, R., Leverich, G. S., Grunze, H., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030322 · Cited by 194
“org ine or bupropion) were no more likely than placebo to be associated with a switch from depression to mania or hypomania (6).”
D'Addario, C., Dell'Osso, B., Palazzo, M. C., Benatti, B., Lietti, L., Cattaneo, E., Galimberti, D., Fenoglio, C., Cortini, F., Scarpini, E., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.10 · Cited by 192
“…the last several years, many reports pointed out the paucity of controlled data in terms of safety and efficacy in BD subjects (Ghaemi et al, 2003; Sachs et al, 2007), particularly in light of increased rates of mood switch, rapid cycling, and suicidal ideation, with current major guidelines…”
Clinical Potential of Neurosteroids for CNS Disorders
Reddy, D. S., & Estes, W. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.04.003 · Cited by 188
“The pathophysiology of BPD may show key differences from major depressive disorder, rendering traditional antidepressant pharmacotherapy less effective for BPD depressive episodes [114].”
BackgroundSit, D. K., McGowan, J., Wiltrout, C., Diler, R. S., Dills, J. (., Luther, J., Yang, A., Ciolino, J. D., Seltman, H., Wisniewski, S. R., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16101200 · Cited by 186
“Antimanicmedicationsreducedepressive symptoms inonlyone-third of patients (2).”
Self-citationDetecting Bipolar Depression From Geographic Location Data
Palmius, N., Tsanas, A., Saunders, K. E. A., Bilderbeck, A. C., Geddes, J. R., Goodwin, G. M., & De Vos, M. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2611862 · Cited by 180
“Bipolar depression is challenging to treat because of the absence of specific treatments [13] and the risk of precipitating a mixed or manic episode [14], [15].”
BackgroundMiklowitz, D. J., & Scott, J. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00715.x · Cited by 180
“A comparison of treatment models: The STEP-BD Program Most of the above-cited trials reported time to first BD relapse or actuarial relapse rates for an active treatment compared with an inactive treatment condition, or an equally intensive but nonspecific comparison (e.g., the supportive group arm of the Barcelona ps…”
BackgroundSelf-citationPaton, C., Crawford, M. J., Bhatti, S. F., Patel, M. X., & Barnes, T. R. E. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09228 · Cited by 177
“Gender Female 663 (63) 870 (56) Male 391 (37) 676 (44) Ethnicity White/white British 926 (88) 1,355 (88) Black/black British 26 (3) 55 (4) Asian 16 (2) 41 (3) Mixed or other 22 (2) 24 (2) Unspecified/unknown 64 (6) 71 (5) Age, y 16–25 173 (16) 229 (15) 26–35 268 (25) 383 (25) 36–45 294 (28) 455 (29) 46–55 220 (21) 344…”
Grunebaum, M. F., Ellis, S. P., Keilp, J. G., Moitra, V. K., Cooper, T. B., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., et al. (2017) · Bipolar Disorders · doi:10.1111/bdi.12487 · Cited by 174
Effects of Forest Therapy on Depressive Symptoms among Adults: A Systematic Review
Lee, I., Choi, H., Bang, K.-S., Kim, S., Song, M., & Lee, B. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14030321 · Cited by 170
Long‐term antidepressant treatment in bipolar disorder: meta‐analyses of benefits and risks
Ghaemi, S. N., Wingo, A. P., Filkowski, M. A., & Baldessarini, R. J. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01257.x · Cited by 173
“As there were multiple treatment arms in three (37, 39, 40) of the seven included trials, there were 12 contrasts involving AD-alone or with an MS vs. placebo or MS-alone to support assessment of risks of new depression (Table 2) and new mania (Table 3).”
BackgroundInfluentialTreatment of bipolar disorder: a systematic review of available data and clinical perspectives
Fountoulakis, K. N., & Vieta, E. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009231 · Cited by 169
“The effect of aripiprazole is considered to be specific andnot attributed to sedation alone (Sachs et al., 2007a).”
BackgroundResultPerugi, G., Medda, P., Toni, C., Mariani, M., Socci, C., & Mauri, M. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666161017233642 · Cited by 167
“This is rather unexpected, because literature data showed significant differences in antidepressants’ efficacy between MDD and BD depression [16].”
BackgroundResultBipolar Disorder — A Focus on Depression
Frye, M. A. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1000402 · Cited by 170
New treatment guidelines for acute bipolar depression: A systematic review
Nivoli, A. M. A., Colom, F., Murru, A., Pacchiarotti, I., Castro-Loli, P., González-Pinto, A., Fountoulakis, K. N., & Vieta, E. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.05.018 · Cited by 161
“A generic association of ADs, preferably SSRIs, is recommended as first-choice treatment in combination with antimanic agents, such as lithium, valproate (Sachs et al., 2007; Goldberg et al., 2007) and atypical antipsychotics.”
BackgroundInfluentialDiagnosis and management of bipolar disorders
Goes, F. S. (2023) · BMJ · doi:10.1136/bmj-2022-073591 · Cited by 203
Austin, P. C., Manca, A., Zwarenstein, M., Juurlink, D. N., & Stanbrook, M. B. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.002 · Cited by 159
“[91] Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB,”
BackgroundBipolar Depression: Overview and Commentary
Baldessarini, R. J., Vieta, E., Calabrese, J. R., Tohen, M., & Bowden, C. L. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673221003747955 · Cited by 156
Self-citationBipolar disorder and mechanisms of action of mood stabilizers
Rapoport, S. I., Basselin, M., Kim, H.-W., & Rao, J. S. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.06.003 · Cited by 155
“…approved mood stabilizers as monotherapy in bipolar mania (Bowden et al., 2005a; Ketter et al., 2001), the limited treatment of bipolar depression (Sachs et al., 2007), the many untoward side effects of approved agents, and the high morbidity, suicide rate and cost to society of BD, render…”
Evolving applications of light therapy
Terman, M. (2007) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2007.06.003 · Cited by 152
“The addition of antidepressant drugs to mood stabilizers often leaves the patient depressed, and on a statistical basis, the response to two well-established antidepressants, paroxetine and bupropion (in combination with a mood stabilizer) was no better than to monotherapy with the stabilizer.(23) While it has sometim…”
BackgroundUnrecognised bipolar disorder in primary care patients with depression
Smith, D. J., Griffiths, E., Kelly, M., Hood, K., Craddock, N., & Simpson, S. A. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.083840 · Cited by 152
Grunze, H. (2011) · FOCUS: The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.9.4.500 · Cited by 149
Self-citationECNP consensus meeting. Bipolar depression. Nice, March 2007
Goodwin, G. M., Anderson, I. M., Arango, C., Bowden, C. L., Henry, C., Mitchell, P. B., Nolen, W. A., Vieta, E., & Wïttchen, H. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.03.003 · Cited by 170
“Thus, the largest independent study (STEP-BD) was resoundingly negative for antidepressants added to a variety of other treatments (Sachs et al., 2007).”
Self-citationMcGirr, A., Vöhringer, P. A., Ghaemi, S. N., Lam, R. W., & Yatham, L. N. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30264-4 · Cited by 149
Amsterdam, J. D., & Shults, J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020284 · Cited by 149
Bipolar II Disorder: Epidemiology, Diagnosis and Management
Benazzi, F. (2007) · CNS Drugs · doi:10.2165/00023210-200721090-00003 · Cited by 175
Fountoulakis, K. N., Tohen, M., & Zarate, C. A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.003 · Cited by 146
Parikh, S. V., Zaretsky, A., Beaulieu, S., Yatham, L. N., Young, L. T., Patelis-Siotis, I., MacQueen, G. M., Levitt, A., Arenovich, T., Cervantes, P., et al. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07343 · Cited by 145
Goldberg, J. F., Brooks, J. O., Kurita, K., Hoblyn, J. C., Ghaemi, S. N., Perlis, R. H., Miklowitz, D. J., Ketter, T. A., Sachs, G. S., & Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04301 · Cited by 145
Self-citationMultifactorial Determinants of the Neurocognitive Effects of Electroconvulsive Therapy
McClintock, S. M., Choi, J., Deng, Z.-D., Appelbaum, L. G., Krystal, A. D., & Lisanby, S. H. (2014) · The Journal of ECT · doi:10.1097/yct.0000000000000137 · Cited by 141
“The Systematic Treatment Enhancement Program for Bipolar Disorder found treatment with an antidepressant (paroxetine or bupropion) and a mood stabilizer (eg, any US Food and Drug Administration–approved antimanic agent) produced a 32% remission rate.(2) The Clinical Antipsychotic Trials of Intervention Effectiveness t…”
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Why antidepressants are not antidepressants: STEP‐BD, STAR*D, and the return of neurotic depression
Nassir Ghaemi, S. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00639.x · Cited by 144
Animal models of bipolar mania: The past, present and future
Logan, R. W., & McClung, C. A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.041 · Cited by 136
Overview of Glutamatergic Dysregulation in Central Pathologies
Miladinovic, T., Nashed, M., & Singh, G. (2015) · Biomolecules · doi:10.3390/biom5043112 · Cited by 137
“depression [62–64].”
The BALANCE investigators and collaborators, Geddes, J. R., Goodwin, G. M., Rendell, J., Azorin, J.-M., Cipriani, A., Ostacher, M. J., Morriss, R., Alder, N., & Juszczak, E. (2011) · Focus · doi:10.1176/foc.9.4.foc488 · Cited by 132
Self-citationPredictive animal models of mania: hits, misses and future directions
Young, J. W., Henry, B. L., & Geyer, M. A. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01318.x · Cited by 132
“In comparison, older drugs such as lithium have retained their clinical efficacy even when assessed in more recent and rigorous clinical trials (Bowden et al., 1994; Sachs et al., 2007).”
BackgroundEfficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry
Fountoulakis, K. Ν., Kasper, S. F., Andreassen, O. A., Blier, P., Okasha, A., Severus, E., Versiani, M., Tandon, R., Möller, H., & Vieta, E. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0323-x · Cited by 149
“Thus, this study does not support the usefulness of adjunctive antidepressant therapy [429], while on the contrary another earlier one supported the usefulness of paroxetine as add-on therapy [566].”
ResultBaek, J. H., Park, D. Y., Choi, J.-M., Kim, J. S., Choi, J. S., Ha, K., Kwon, J. S., Lee, D., & Hong, K. S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.11.020 · Cited by 141
Response to ECT in bipolar I, bipolar II and unipolar depression
Medda, P., Perugi, G., Zanello, S., Ciuffa, M., & Cassano, G. B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.014 · Cited by 128
Sampaio-Junior, B., Tortella, G., Borrione, L., Moffa, A. H., Machado-Vieira, R., Cretaz, E., Fernandes da Silva, A., Fraguas, R., Aparício, L. V., Klein, I., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4040 · Cited by 125
Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
Li, X., Frye, M. A., & Shelton, R. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.198 · Cited by 144
“In the NIMH-funded 26-week Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study (”
BackgroundClinical practice recommendations for bipolar disorder
Malhi, G. S., Adams, D., Lampe, L., Paton, M., O’Connor, N., Newton, L. A., Walter, G., Taylor, A., Porter, R., Mulder, R. T., et al. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01383.x · Cited by 129
Harel, E. V., Zangen, A., Roth, Y., Reti, I., Braw, Y., & Levkovitz, Y. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.510893 · Cited by 126
“A recent large effectiveness study (STEP-BD) found no superiority of adjunct antidepressants to a mood stabilizer in the treatment of BPD, leaving clinicians with limited tools for dealing with this long-lasting, disabling phase of the illness (Sachs et al. 2007).”
BackgroundBond, D. J., Lam, R. W., & Yatham, L. N. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.11.008 · Cited by 122
Taylor, D. M., Cornelius, V., Smith, L., & Young, A. H. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12343 · Cited by 122
“placebo (59) (in some contrast to findings here).”
ResultAntidepressant Response and the Serotonin Transporter Gene-Linked Polymorphic Region
Taylor, M. J., Sen, S., & Bhagwagar, Z. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.034 · Cited by 118
“antidepressants in bipolar depression in recent studies (58).”
BackgroundLicht, R. W., Gijsman, H., Nolen, W. A., & Angst, J. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01237.x · Cited by 120
“7% in patients randomized to a mood stabilizer alone (n = 187) (11).”
BackgroundTreatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials
Vieta, E., Locklear, J., Günther, O., Ekman, M., Miltenburger, C., Chatterton, M. L., Åström, M., & Paulsson, B. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181f15849 · Cited by 119
“with bipolar depression.(29) If we are to view bipolar depression separately from unipolar depression, we need to establish which of the current treatment options meet the antidepressant criteria and also whether current treatment guidelines are in line with evidence-based findings.”
BackgroundResultAntidepressants in bipolar depression: An enduring controversy
Gitlin, M. J. (2018) · International Journal of Bipolar Disorders · doi:10.1186/s40345-018-0133-9 · Cited by 116
Fountoulakis, K. N., Yatham, L., Grunze, H., Vieta, E., Young, A., Blier, P., Kasper, S., & Moeller, H. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 116
“However, a number of larger RCTs reported negative data concerning switching with paroxetine and bupropion (Sachs et al., 2007), fluoxetine, even as monotherapy in BD-II patients (Amsterdam et al.”
Lithium specificity in bipolar illness: a classic agent for the classic disorder
Gershon, S., Chengappa, K. R., & Malhi, G. S. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00709.x · Cited by 116
“Further, some degree of phenotypic specificity can perhaps be insinuated from their lack of efficacy in the treatment of bipolar depression (23, 28, 29).”
BackgroundGueorguieva, R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.132 · Cited by 115
“Antidepressants are reported to have reduced efficacy in treating depression among patients with bipolar disorder, and they may increase mood cycling.(51,52) Similarly, adverse effects of other forms of psychopathologic conditions, particularly personality disorders, or the social use of alcohol cannot be determined u…”
BackgroundSackeim, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., Demitrack, M. A., George, M. S., Prudic, J., Thase, M. E., & Rush, A. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.021 · Cited by 109
“Overall, the evidence for efficacy is relatively sparse and, at times, inconsistent (Sachs et al., 2007; Sidor and Macqueen, 2011; Vazquez et al., 2011, 2013).”
BackgroundSelf-citationSubthreshold bipolarity: diagnostic issues and challenges
Nusslock, R., & Frank, E. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00957.x · Cited by 108
“Sachs and colleagues (35), using data from the multisite Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), also reported that standard antidepressant medication was not associated with increased risk of treatment-emergent affective switch.”
Subtyping Major Depressive Disorder
Lichtenberg, P., & Belmaker, R. H. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000286957 · Cited by 109
“A recent double-blind placebo-controlled study showed that SSRIs or bupropion do not seem to be effective in bipolar depression [”
BackgroundMöller, H.-J. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802264606 · Cited by 107
“It is for example not enough to take DSM-IV symptom criteria for major depression, to provide a scoring for these symptoms and to calculate the correlation with values of corresponding cross-sectional scales, e.g., with the HAMD, like it was done for SUM-D (Sachs et al. 2002, 2007).”
MethodEvidence‐based treatment strategies for treatment‐resistant bipolar depression: a systematic review
Sienaert, P., Lambrichts, L., Dols, A., & De Fruyt, J. (2013) · Bipolar Disorders · doi:10.1111/bdi.12026 · Cited by 102
“The addition of antidepressants to an ongoing treatment with mood stabilizers will be helpful in only a quarter of patients with bipolar depression (11).”
Background
Metadata
- Authors
- Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., Ketter, T. A., Patel, J., Hauser, P., Rapport, D., Martinez, J. M., Allen, M. H., Miklowitz, D. J., Otto, M. W., Dennehy, E. B., & Thase, M. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- University Hospitals Cleveland Medical Center (US)
- Baylor College of Medicine (US)
- University of Pittsburgh (US)
- University of Pennsylvania (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Oklahoma (US)
- Stanford Medicine (US)
- University of Massachusetts Chan Medical School (US)
- University of Toledo (US)
- University of Colorado Boulder (US)
- Boston University (US)
- Purdue University West Lafayette (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-26
- Volume
- 356
- Issue
- 17
- Pages
- 1711-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166423384
- Semantic Scholar
- c224a40d0ffd6471e7b72b38060d169ba1cdec34
- Cited by
- 937
- References
- 27
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 33 · 2023: 17 · 2022: 15 · 2021: 68 · 2020: 33 · 2019: 29 · 2018: 36 · 2017: 28 · 2016: 53 · 2015: 47 · 2014: 51 · 2013: 52 · 2012: 61
- FWCI
- 56.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh80001-12-0-0)
- National Institute of Mental Health (N01-MH80001)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- bipolar depression, adjunctive antidepressant therapy, mood stabilizers, euthymia, bipolar disorder, antidepressant safety
- MeSH terms
- Adult, Bipolar Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Bupropion, Treatment Outcome, Paroxetine, Antidepressive Agents, Second-Generation, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.